Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
- PMID: 32823274
- PMCID: PMC7857155
- DOI: 10.1093/infdis/jiaa532
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
Abstract
Background: HIV-1 proviruses persist in people on antiretroviral therapy (ART) but most are defective and do not constitute a replication-competent reservoir. The decay of infected cells carrying intact compared with defective HIV-1 proviruses has not been well defined in people on ART.
Methods: We separately quantified intact and defective proviruses, residual plasma viremia, and markers of inflammation and activation in people on long-term ART.
Results: Among 40 participants tested longitudinally from a median of 7.1 years to 12 years after ART initiation, intact provirus levels declined significantly over time (median half-life, 7.1 years; 95% confidence interval [CI], 3.9-18), whereas defective provirus levels did not decrease. The median half-life of total HIV-1 DNA was 41.6 years (95% CI, 13.6-75). The proportion of all proviruses that were intact diminished over time on ART, from about 10% at the first on-ART time point to about 5% at the last. Intact provirus levels on ART correlated with total HIV-1 DNA and residual plasma viremia, but there was no evidence for associations between intact provirus levels and inflammation or immune activation.
Conclusions: Cells containing intact, replication-competent proviruses are selectively lost during suppressive ART. Defining the mechanisms involved should inform strategies to accelerate HIV-1 reservoir depletion.
Keywords: HIV proviruses; HIV reservoirs; immune activation; inflammation; residual viremia.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Figures





References
-
- Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512–7. - PubMed
-
- Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UM1 AI069494/AI/NIAID NIH HHS/United States
- UM1 AI126620/AI/NIAID NIH HHS/United States
- R44 AI124996/AI/NIAID NIH HHS/United States
- UM1 AI126611/AI/NIAID NIH HHS/United States
- UM1 AI069496/AI/NIAID NIH HHS/United States
- UM1 AI126603/AI/NIAID NIH HHS/United States
- U24 AI143502/AI/NIAID NIH HHS/United States
- UM1 AI106701/AI/NIAID NIH HHS/United States
- UM1 AI069412/AI/NIAID NIH HHS/United States
- UM1 AI068634/AI/NIAID NIH HHS/United States
- R43 AI142866/AI/NIAID NIH HHS/United States
- UM1 AI069481/AI/NIAID NIH HHS/United States
- UL1 TR002384/TR/NCATS NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
- U01 AI068634/AI/NIAID NIH HHS/United States
- UM1 AI068636/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical